Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ford Motor Company

The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.

3 Top Value Stocks to Buy Right Now

Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive opportunity for income and value investors.

Why Bargain-Priced Viatris Could Deliver Strong Returns

The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.

US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs

Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.

Why Viatris Stock Is Jumping Today

Total revenue declined by 3% year over year to $3.8 billion. Viatris reported a net loss of $326 million compared to $264 million earnings last year.

Viatris Reports Mixed Q2 Results

Viatris Inc. (NASDAQ:VTRS ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Chief Executive Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Doretta Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Umer Raffat - Evercore ISI Balaji Prasad - Barclays Bhavin Patel - Bank of America Operator Good morning, everyone, and welcome to the Viatris Q2 2024 Earnings Call. All participants will be in a listen-only mode.

Viatris Inc. (VTRS) Q2 2024 Earnings Call Transcript

Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.

Viatris (VTRS) Q2 Earnings Surpass Estimates

Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.

Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand

PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1] Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across Segments U.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2] Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder Return Raises 2024 Full-Year New Product Revenues Range to $500 Million-$600 Million Expects 2024 Full-Year Total Revenues Growth of ~2% on a Divestiture-Adjusted Operational Basis[3] Viatris Inc. (NASDAQ: VTRS) today announced strong financial results for the second quarter of 2024, including total revenues of $3.8 billion and new product revenues of $210 million, demonstrating the Company's ability to continue to grow its diversified base business.  With the substantial completion of its divestitures the Company believes it has increased its financial strength and has a strong foundation from which to accelerate growth and shareholder return.

Viatris Reports Second Quarter Financial Results for 2024

PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.

Viatris Announces Second Quarter 2024 Dividend

Novartis

Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Amgen

Gilead Sciences

Eli Lilly

Novo Nordisk

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline

Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Viatris Inc (VTRS:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry" company profile from Plunkett Research Ltd has been added to ResearchAndMarkets.com's offering. This unique new report provides deep financial benchmarks for Viatris Inc (VTRS:NAS) compared to its top competitors and compared to the average for all companies within its primary industry. - This benchmarking study for Viatris Inc (VTRS:NAS) includes growth forecast for its primary industry for the current year and the next 7 years.

Viatris Inc (VTRS:NAS) Company Profile: Analytics, Extensive Financial Metrics, and Benchmark Against Averages and Top Companies Within its Industry

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024.

Idorsia announces financial results for the first half 2024

Amphastar Pharma

Teva Pharmaceutical

With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH , July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures. In October, the Company announced it had entered into agreements to divest substantially all of its OTC business, as well as its Women's Healthcare business, its Active Pharmaceutical Ingredients (API) business in India and commercialization rights in certain non-core markets.

Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture

Mylan

Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

PITTSBURGH , July 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.

U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation

PITTSBURGH , June 25, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024. This recognition is presented by TIME and Statista Inc., the world-leading statistics portal and industry ranking provider.

Viatris Named to TIME's World's Most Sustainable Companies 2024 List

Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM ET Company Participants Scott Smith - CEO Theodora Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Why don't we get started?

Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

PITTSBURGH , June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer  Scott A.

News for Viatris Stock (VTRS)